表紙
市場調査レポート

核医学/放射性医薬品の世界市場予測 2020年:SPECT用放射性医薬品・PET用放射性医薬品・ベータ放射体・アルファ放射体・小線源療法

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

発行 MarketsandMarkets 商品コード 209171
出版日 ページ情報 英文 191 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
核医学/放射性医薬品の世界市場予測 2020年:SPECT用放射性医薬品・PET用放射性医薬品・ベータ放射体・アルファ放射体・小線源療法 Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020
出版日: 2015年07月07日 ページ情報: 英文 191 Pages
概要

世界の核医学/放射性医薬品市場は、様々な臨床的適応への放射性同位体の認証数の増加によって、拡大しています。2015年において、同市場では診断用放射性医薬品セグメントが最大のシェアを構成しました。地域別では北米が最大のシェアを構成し、アジア太平洋地域、欧州、およびその他地域 (ROW) が続きました。今後数年間においては、アジア太平洋地域が最も高い成長率を示すと予測されています。インド、中国、日本およびオーストラリアは放射性医薬品メーカーにとって利益の多い市場になると予測されています。

当レポートは、世界の核医学/放射性医薬品市場について調査分析し、種類、手続き数、用途および地域別の市場分析、競合情勢および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 世界の核医学/放射性医薬品市場
  • SPECT用核医学/放射性医薬品診断市場:地域別
  • 核医学/放射性医薬品市場の地域別スナップショット
  • 核医学/放射性医薬品市場:種類別

第5章 市場概要

  • イントロダクション
  • 市場ダイナミクス
    • 促進因子
    • 阻害因子
    • 機会
    • 脅威

第6章 世界の核医学/放射性医薬品市場:種類別

  • イントロダクション
  • 診断用放射性医薬品市場
    • SPECT用放射性医薬品
    • PET用放射性医薬品
  • 治療用放射性医薬品市場
    • ベータ放射体
    • アルファ放射体
    • 小線源療法

第7章 世界の核医学/放射性医薬品市場:手続き数

  • イントロダクション
  • 診断用放射性医薬品市場
    • SPECT用
    • PET用
  • 治療用放射性医薬品市場
    • ベータ放射体
    • アルファ放射体
    • 小線源療法

第8章 世界の核医学/放射性医薬品市場:用途別

  • イントロダクション
  • 診断用途
    • SPECT
    • PET
  • 治療用途
    • 甲状腺
    • 癌の骨転移
    • リンパ腫
    • 内分泌腫瘍
    • その他の治療用途

第9章 世界の核医学/放射性医薬品市場:地域別

  • イントロダクション
  • 診断用放射性医薬品市場
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他 (ROW)
  • 治療用放射性医薬品市場

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向

第11章 企業プロファイル

  • イントロダクション
  • CARDINAL HEALTH, INC.
  • MALLINCKRODT PLC
  • GE HEALTHCARE
  • LANTHEUS MEDICAL IMAGING, INC.
  • BAYER HEALTHCARE
  • BRACCO IMAGING S.P.A
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION, INC.
  • ADVANCED ACCELERATOR APPLICATIONS S.A.
  • IBA MOLECULAR IMAGING

第12章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 3590

Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015.

In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.

In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets for the manufacturers of radiopharmaceuticals.

The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings. These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, and application, and procedural volume
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine/radiopharmaceuticals technologies across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine/radiopharmaceuticals market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
  • 2.2. SECONDARY AND PRIMARY RESEARCH METHODOLOGY
    • 2.2.1. SECONDARY RESEARCH
    • 2.2.2. PRIMARY RESEARCH
    • 2.2.3. KEY INDUSTRY INSIGHTS
  • 2.3. KEY DATA FROM PRIMARY SOURCES
  • 2.4. KEY INSIGHTS FROM PRIMARY SOURCES
  • 2.5. MARKET SIZE ESTIMATION METHODOLOGY
  • 2.6. RESEARCH DESIGN
  • 2.7. MARKET DATA VALIDATION AND TRIANGULATION
  • 2.8. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • 4.2. SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTICS MARKET, BY REGION AND APPLICATION
  • 4.3. REGIONAL SNAPSHOT OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • 4.4. NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing preference for SPECT and PET scans
      • 5.2.1.2. Advances in radiotracers
      • 5.2.1.3. Alpha radio immunotherapy-based targeted cancer treatment
      • 5.2.1.4. Increasing incidence of cancer and cardiac ailments
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Shorter half-life of radiopharmaceuticals restricts its usage
      • 5.2.2.2. Stringent regulatory and GMP guidelines
      • 5.2.2.3. Competition from conventional diagnostic procedures
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Potential radioisotopes in the pipeline
      • 5.2.3.2. High demand in emerging markets
      • 5.2.3.3. Neurological applications
    • 5.2.4. THREAT
      • 5.2.4.1. Shutdown of nuclear reactors

6. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 6.2.1. SPECT RADIOPHARMACEUTICALS
      • 6.2.1.1. Technetium-99m (Tc-99m)
      • 6.2.1.2. Thallium-201(Tl-201)
      • 6.2.1.3. Gallium-67(Ga-67)
      • 6.2.1.4. Iodine (I-123)
      • 6.2.1.5. Others
    • 6.2.2. PET RADIOPHARMACEUTICALS
      • 6.2.2.1. Fluorine-18(F-18)
      • 6.2.2.2. Rubidium-82(Rb-82)
      • 6.2.2.3. Others
  • 6.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 6.3.1. BETA EMITTERS
      • 6.3.1.1. Iodine-131(I-131)
      • 6.3.1.2. Yttrium-90(Y-90)
      • 6.3.1.3. Samarium-153(Sm-153)
      • 6.3.1.4. Rhenium-186(Re-186)
      • 6.3.1.5. Lutetium-177(Lu-177)
      • 6.3.1.6. Others
    • 6.3.2. ALPHA EMITTERS
      • 6.3.2.1. Radium-223(Ra-223)
    • 6.3.3. BRACHYTHERAPY
      • 6.3.3.1. Iodine-125
      • 6.3.3.2. Iridium-192
      • 6.3.3.3. Palladium-103
      • 6.3.3.4. Cesium-131
      • 6.3.3.5. Others

7. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 7.2.1. SPECT RADIOPHARMACEUTICALS
    • 7.2.2. PET RADIOPHARMACEUTICALS
  • 7.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 7.3.1. BETA EMITTERS
    • 7.3.2. ALPHA EMITTERS
    • 7.3.3. BRACHYTHERAPY

8. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTIC APPLICATIONS
    • 8.2.1. SPECT APPLICATIONS
      • 8.2.1.1. Cardiology
      • 8.2.1.2. Lymphoma
      • 8.2.1.3. Neurology
      • 8.2.1.4. Thyroid
      • 8.2.1.5. Other Diagnostic Applications
    • 8.2.2. PET APPLICATIONS
      • 8.2.2.1. Oncology
      • 8.2.2.2. Cardiology
      • 8.2.2.3. Neurology
      • 8.2.2.4. Other PET Applications
  • 8.3. THERAPEUTIC APPLICATIONS
    • 8.3.1. THYROID
    • 8.3.2. BONE METASTASIS
    • 8.3.3. LYMPHOMA
    • 8.3.4. ENDOCRINE TUMORS
    • 8.3.5. OTHER THERAPEUTIC APPLICATIONS

9. GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 9.2.1. NORTH AMERICA
      • 9.2.1.1. DEVELOPMENT OF MO-99 PRODUCTION FACILITIES IN THE U.S.
      • 9.2.1.2. FDA APPROVALS OF NEW RADIOPHARMACEUTICALS
      • 9.2.1.3. EXTENSION OF OPERATIONS IN THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR
      • 9.2.1.4. DEVELOPMENT OF ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA
    • 9.2.2. EUROPE
      • 9.2.2.1. INCREASING ACCEPTABILITY OF 18F-FDG PET-CT IN THE U.K.
      • 9.2.2.2. SHUTDOWN OF FRENCH NUCLEAR REACTOR
      • 9.2.2.3. NEW IRRADIATION FACILITY IN GERMANY
    • 9.2.3. ASIA-PACIFIC
      • 9.2.3.1. INTRODUCTION OF NEW COST-EFFECTIVE TC-99 GENERATORS IN INDIA
      • 9.2.3.2. HIGH INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE IN CHINA
      • 9.2.3.3. INCREASING MO-99 PRODUCTION IN AUSTRALIA
      • 9.2.3.4. INITIATIVES TO PROMOTE HEALTH IN ASIA-PACIFIC
    • 9.2.4. REST OF THE WORLD
      • 9.2.4.1. DEVELOPMENT OF MULTIPURPOSE RESEARCH REACTOR IN BRAZIL
      • 9.2.4.2. ARGENTINA'S INCREASING IRRADIATION CAPACITY
      • 9.2.4.3. CONVERSION OF THE SAFARI 1 REACTOR, FROM HEU-BASED MO-99 PRODUCTION TO LEU
  • 9.3. THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
    • 9.3.1. NORTH AMERICA
      • 9.3.1.1. FDA approval for alpha emitters in the U.S.
      • 9.3.1.2. Therapeutic nuclear medicine, an alternative choice of treatment in oncology
      • 9.3.1.3. Increase in the incidence of thyroid cancer
      • 9.3.1.4. Expertise in isotope production
      • 9.3.1.5. Government initiatives
      • 9.3.1.6. High incidence of cancer
    • 9.3.2. EUROPE
      • 9.3.2.1. Increasing awareness of radioisotope therapy in the U.K.
      • 9.3.2.2. Adverse reactions to radiopharmaceuticals in France
      • 9.3.2.3. Radionuklidtherapeutika-research program conducted in Germany
      • 9.3.2.4. Russia, an upcoming country for radionuclide therapy
    • 9.3.3. ASIA-PACIFIC
      • 9.3.3.1. Increased production of radiopharmaceuticals for therapeutic purposes in India
      • 9.3.3.2. Aging population and increasing cancer incidence
      • 9.3.3.3. Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA)
    • 9.3.4. REST OF THE WORLD(ROW)
      • 9.3.4.1. Growing aging population
      • 9.3.4.2. Increase in cancer incidences

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
    • 10.2.1. INTRODUCTION
    • 10.2.2. CARDINAL HEALTH, INC.
    • 10.2.3. MALLINCKRODT PLC
    • 10.2.4. GE HEALTHCARE
    • 10.2.5. LANTHEUS MEDICAL IMAGING, INC.
    • 10.2.6. BAYER HEALTHCARE
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. INTRODUCTION
    • 10.3.2. AGREEMENTS, CONTRACTS, AND PARTNERSHIPS
    • 10.3.3. ACQUISITIONS
    • 10.3.4. MARKET DEVELOPMENT
    • 10.3.5. EXPANSION
    • 10.3.6. NEW PRODUCT LAUNCHES
    • 10.3.7. OTHERS

11. COMPANY PROFILES

  • 11.1. INTRODUCTION
  • 11.2. CARDINAL HEALTH, INC.
    • 11.2.1. BUSINESS OVERVIEW
    • 11.2.2. PRODUCTS AND SERVICES
    • 11.2.3. RECENT DEVELOPMENTS
    • 11.2.4. MNM VIEW
  • 11.3. MALLINCKRODT PLC
    • 11.3.1. BUSINESS OVERVIEW
    • 11.3.2. PRODUCT OFFERINGS
    • 11.3.3. RECENT DEVELOPMENTS
    • 11.3.4. MNM VIEW
  • 11.4. GE HEALTHCARE
    • 11.4.1. BUSINESS OVERVIEW
    • 11.4.2. PRODUCT PORTFOLIO
    • 11.4.3. RECENT DEVELOPMENTS
    • 11.4.4. MNM VIEW
  • 11.5. LANTHEUS MEDICAL IMAGING, INC.
    • 11.5.1. BUSINESS OVERVIEW
    • 11.5.2. PRODUCT OFFERINGS
    • 11.5.3. RECENT DEVELOPMENTS
    • 11.5.4. MNM VIEW
  • 11.6. BAYER HEALTHCARE
    • 11.6.1. BUSINESS OVERVIEW
    • 11.6.2. PRODUCT OFFERINGS
    • 11.6.3. RECENT DEVELOPMENTS
    • 11.6.4. MNM VIEW
  • 11.7. BRACCO IMAGING S.P.A
    • 11.7.1. BUSINESS OVERVIEW
    • 11.7.2. PRODUCT OFFERINGS
    • 11.7.3. RECENT DEVELOPMENTS
  • 11.8. ECZACIBASI-MONROL NUCLEAR PRODUCTS
    • 11.8.1. BUSINESS OVERVIEW
    • 11.8.2. PRODUCTS AND SERVICES
    • 11.8.3. RECENT DEVELOPMENTS
  • 11.9. NORDION, INC.
    • 11.9.1. BUSINESS OVERVIEW
    • 11.9.2. PRODUCT OFFERINGS
    • 11.9.3. RECENT DEVELOPMENTS
  • 11.10. ADVANCED ACCELERATOR APPLICATIONS S.A.
    • 11.10.1. BUSINESS OVERVIEW
    • 11.10.2. PRODUCT OFFERINGS
    • 11.10.3. RECENT DEVELOPMENTS
  • 11.11. IBA MOLECULAR IMAGING
    • 11.11.1. BUSINESS OVERVIEW
    • 11.11.2. PRODUCT OFFERINGS
    • 11.11.1. RECENT DEVELOPMENTS

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. COMPANY DEVELOPMENTS (2012-2015)
    • 12.2.1. CARDINAL HEALTH, INC.
    • 12.2.2. BAYER HEALTHCARE
  • 12.3. AVAILABLE CUSTOMIZATIONS
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • TABLE 2: SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE NUCLEAR MEDICINE MARKET
  • TABLE 3: POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE NUCLEAR MEDICINE MARKET
  • TABLE 4: SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET
  • TABLE 5: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 6: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC SEGMENT, BY REGION, 2013-2020 ($MILLION)
  • TABLE 7: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 8: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 9: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY ISOTOPE TYPE, 2013-2020 ($MILLION)
  • TABLE 10: GLOBAL SPECT MARKET SIZE FOR TECHNETIUM-99M ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 11: GLOBAL SPECT MARKET SIZE FOR THALLIUM-201 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 12: GLOBAL SPECT MARKET SIZE FOR GALLIUM-67 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 13: GLOBAL SPECT MARKET SIZE FOR IODINE-123 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 14: GLOBAL SPECT MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 15: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 16: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY ISOTOPE, 2013-2020 ($MILLION)
  • TABLE 17: GLOBAL PET MARKET SIZE FOR FLUORINE-18 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 18: GLOBAL PET MARKET SIZE FOR RUBIDIUM-82 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 19: GLOBAL PET ISOTOPES MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 20: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 21: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 22: GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 23: GLOBAL BETA EMITTERS MARKET SIZE, BY ISOTOPE, 2013-2020 ($MILLION)
  • TABLE 24: GLOBAL BETA EMITTERS MARKET SIZE FOR IODINE-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 25: GLOBAL BETA EMITTERS MARKET SIZE FOR YTTRIUM-90 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 26: GLOBAL BETA EMITTERS MARKET SIZE FOR SAMARIUM-153 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 27: GLOBAL BETA EMITTERS MARKET SIZE FOR RHENIUM-186 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 28: GLOBAL BETA EMITTERS MARKET SIZE FOR LUTETIUM-177 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 29: GLOBAL BETA EMITTERS MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 30: GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 31: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY REGION, 2013-2020 ($MILLION)
  • TABLE 32: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY ISOTOPES, 2013-2020 ($MILLION)
  • TABLE 33: GLOBAL BRACHYTHERAPY MARKET SIZE FOR IODINE-125 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 34: GLOBAL BRACHYTHERAPY MARKET SIZE FOR IRIDIUM-192 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 35: GLOBAL BRACHYTHERAPY MARKET SIZE FOR PALLADIUM-103 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 36: GLOBAL BRACHYTHERAPY MARKET SIZE FOR CESIUM-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 37: GLOBAL BRACHYTHERAPY MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
  • TABLE 38: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 39: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 40: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 41: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 42: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 43: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 44: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 45: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 46: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 47: NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 48: NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 49: NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 50: NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 51: NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY TYPE, 2013-2020 (THOUSAND)
  • TABLE 52: NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY REGION, 2013-2020 (THOUSAND)
  • TABLE 53: SEGMENTATION OF NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE
  • TABLE 54: NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 55: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 56: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 57: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 58: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 59: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 60: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION OF PET, BY APPLICATION
  • TABLE 61: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 62: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 63: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 64: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 65: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 66: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020($MILLION)
  • TABLE 67: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 68: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 69: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 70: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE TUMOR THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 71: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013-2020 ($MILLION)
  • TABLE 72: GLOBAL NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
  • TABLE 73: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 74: NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 75: NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 76: NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 77: NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 78: EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 79: EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 80: EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 81: EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 82: EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 83: ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 84: ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 85: ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 86: ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 87: ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 88: ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 89: ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 90: ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 91: ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 92: ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 93: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 94: NORTH AMERICA: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 95: NORTH AMERICA: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 96: NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 97: EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 98: EUROPE: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 99: EUROPE: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 100: EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 101: ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 102: ASIA-PACIFIC: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 103: ASIA-PACIFIC: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 104: ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
  • TABLE 105: ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 106: ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BETA EMITTERS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 107: ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
  • TABLE 108: ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)

LIST OF FIGURES

  • FIGURE 1: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
  • FIGURE 2: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 5: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: DIAGNOSTICS MARKET TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 8: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015-2020
  • FIGURE 9: GEOGRAPHICAL SNAPSHOT OF THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  • FIGURE 10: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS, 2015-2020
  • FIGURE 11: ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
  • FIGURE 12: NORTH AMERICA DOMINATES THE SPECT NUCLEAR MEDICINE DIAGNOSTICS MARKET IN 2015
  • FIGURE 13: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 14: DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
  • FIGURE 15: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES
  • FIGURE 16: GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
  • FIGURE 17: THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.5%
  • FIGURE 18: PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.7% DURING THE FORECAST PERIOD
  • FIGURE 19: ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 17.3% DURING THE FORECAST PERIOD
  • FIGURE 20: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 9.4% DURING THE FORECAST PERIOD
  • FIGURE 21: THE NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.4% DURING THE FORECAST PERIOD
  • FIGURE 22: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 13.1% DURING THE FORECAST PERIOD
  • FIGURE 23: THE NEUROLOGY APPLICATION SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR OF 12.9% DURING THE FORECAST PERIOD
  • FIGURE 24: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC APPLICATIONS MARKET SEGMENTATION, BY TYPE
  • FIGURE 25: ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 12.2% DURING THE FORECAST PERIOD
  • FIGURE 26: THE ENDOCRINE TUMORS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD
  • FIGURE 27: NORTH AMERICA COMMANDS LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015
  • FIGURE 28: NORTH AMERICA IS LIKELY TO WITNESS A CAGR OF 8.1% DURING THE FORECAST PERIOD
  • FIGURE 29: EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET TO GROW AT A CAGR OF 7.7% DURING THE FORECAST PERIOD
  • FIGURE 30: ASIA-PACIFIC IS LIKELY TO WITNESS A CAGR OF 10.1% DURING THE FORECAST PERIOD
  • FIGURE 31: ROW NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET IS LIKELY TO GROW AT A CAGR OF 9% IN THE FORCAST PERIOD
  • FIGURE 32: NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET IN 2015
  • FIGURE 33: NORTH AMERICA TO WITNESS A CAGR OF 10% IN THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET DURING THE FORECAST PERIOD
  • FIGURE 34: EUROPE IS LIKELY TO WITNESS A CAGR OF 9.8% DURING THE FORECAST PERIOD
  • FIGURE 35: ASIA-PACIFIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET TO GROW AT A CAGR OF 12.2% DURING THE FORECAST PERIOD
  • FIGURE 36: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 37: STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST THREE YEARS (2012-2015)
  • FIGURE 38: BATTLE FOR MARKET SHARE: AGREEMENTS/CONTRACTS/PARTNERSHIPS WAS THE KEY STRATEGY (2012 -2015)
  • FIGURE 39: AGREEMENTS, CONTRACTS, AND PARTNERSHIPS, 2012-2015
  • FIGURE 40: ACQUISITIONS, 2012-2015
  • FIGURE 41: MARKET DEVELOPMENT, 2012-2015
  • FIGURE 42: EXPANSIONS, 2012-2015
  • FIGURE 43: NEW PRODUCT LAUNCHES, 2012-2015
  • FIGURE 44: OTHER STRATEGIES, 2012-2015
  • FIGURE 45: GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET
  • FIGURE 46: CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
  • FIGURE 47: MALLINCKRODT PLC: COMPANY SNAPSHOT
  • FIGURE 48: GE HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 49: LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT
  • FIGURE 50: BAYER HEALTHCARE: COMPANY SNAPSHOT
  • FIGURE 51: NORDION, INC.: COMPANY SNAPSHOT
  • FIGURE 52: ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Back to Top